Knowledge about placebo mechanisms in patients with chronic pain is scarce. Fibromyalgia syndrome (FM) is associated with dysfunctions of central pain inhibition, and since placebo analgesia entails activation of endogenous pain inhibition, we hypothesized that long-term exposure to FM pain would negatively affect placebo responses. Here we examined the placebo-group (n=37, mean age 45 years) from a 12-week, randomized, double-blind, Perspective: This article presents a novel perspective on placebo analgesia, as placebo responses among patients with chronic pain were analyzed. Long-term exposure to fibromyalgia pain was associated with lower placebo analgesia, and the results demonstrate the importance of taking pain duration into account when interpreting the results from placebo-controlled trials.
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Introduction
The ability to endure painful conditions depends largely on activation of endogenous pain inhibitory mechanisms in the central nervous system. Pain inhibition is therefore part of the normal pain response and modulates the relationship between incoming nociceptive signals and perceived pain. In common pain disorders, such as chronic low back pain and fibromyalgia syndrome (FM), there is evidence for augmented cerebral processing of pain 2, 15, 20 . In addition, FM pain has repeatedly been associated with impaired pain inhibition 25, 30, 32 and decreased activity within pain inhibitory pathways in the brain 20, 21 . The inability to c i e endogenous p in inhibi ion is o en e e ed o s 'disinhibi ion' nd is h ll k o FM pathophysiology 20, 30 .
Placebo analgesia is a term that describes pain reduction in response to an inert treatment that mimics a genuine analgesic treatment (e.g. sugar pill) by creating treatment expectations of relief. The neurobiological mechanisms of placebo analgesia were first described by Levine et al. 34 and since then a large literature has verified the original findings by showing activation of cerebral pain inhibitory pathways during placebo analgesia 37, 44 and endogenous release of opioids in the brain 48 .
Since placebo analgesia depends on activation of endogenous pain relief, and FM patients are characterized by dysfunctional pain inhibition, the presence of placebo responses among FM patients may seem paradoxical. In a recent meta-analysis, where placebo responses in drug trials for FM and patients with peripheral diabetic neuropathy were compared, FM patients had relatively lower placebo responses than patients with neuropathy 17 . The authors speculate that the difference may reflect the underlying inability to recruit endogenous analgesia among FM patients, compared to patients with neuropathy who are not characterized by central disinhibition 17 . Yet, there was presence of some degree of placebo responses among FM patients 17, 18 , and as there was considerable variance in responses M A N U S C R I P T A C C E P T E D 
Methods
Patients
A total of 92 patients were randomized and included in the overall clinical trial, whereof 46
were randomized to the placebo arm. Outcome data from 38 patients in the placebo group was available after treatment, yet one patient was excluded from the statistical analyses due to en passant neurological findings. Hence, all statistics are based on 37 patients. Results from the overall clinical trial can be found in previous publications. 22, 38 . Patients eligible for inclusion were females, aged 18-55 years, fulfilling the ACR 1990 criteria for FMM A N U S C R I P T were scheduled between baseline and study end, including checks of compliance, adverse events, pain ratings and vital signs. Patients returned in week 12 (day 83 ± 1 day) for the evaluation of treatment effects followed by a 9-day down-titration phase.
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Responder classification
After treatment (week 12), patients rated their subjective impression of treatment effect, using the Patient Global Impression of Change (PGIC) questionnaire 19, 39 with the options: very M A N U S C R I P T
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7 much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6) and very much worse (7). Treatment responders were a priori defined as patients reporting any type of improvement (i.e. PGIC 1, 2 or 3). Non-responders were defined as patients having no change (i.e. PGIC 4) or worsening of symptoms (i.e. PGIC
5, 6 o 7)
. P IC is co onl used sc le e su ing he p ien s' subjec i e epo o clinic l improvement in relation to a given treatment.
Baseline characteristics
In order to characterize patients at baseline, they rated the duration of their widespread pain 45 .
Primary outcome -pressure pain sensitivity (P50)
The 
Secondary outcome measures
Secondary outcome measures were collected before and after treatment and included: FM p in i bili c lcul ed s e ch p ien 's di e ence be ween weekl ini u nd weekl maximum pain intensities (max-min) (VAS 0-100 mm) at baseline; average weekly pain intensity (VAS); number of painful areas (pain drawing); impact of FM symptoms (Fibromyalgia Impact Questionnaire, FIQ) 7 .
Statistical analyses
Differences at baseline, and differences from baseline to after treatment, were analyzed using one sample t-tests (within groups) and independent samples t-tests (between groups). Due to the nonparametric properties of VAS ratings, the pain ratings (average weekly pain, pain variability) and P50 were analyzed with Wilcoxon signed-rank tests (within groups) and Mann-Whitney U tests (between groups). Correlation analyses were performed using Spe n's r coefficient (when ordinal measures were included), except for the correlation between FM duration and age, which was analyzed with Pearson's r (continuous measures).
All statistical analyses were performed in SPSS 23.0. The significance level was set as p < 0.05, two-tailed.
Results
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Patient characteristics
Among all patients in the placebo arm of this clinical trial, 22 patients were non-responders and 15 were responders according to the PGIC measure. The mean age across responders and non-responders was 45 years, and patients had suffered from widespread pain for an average of 132 months (11 years) ( Table 1) .
Baseline comparisons between placebo responders and non-responders
Placebo responders had lower ratings of depression (BDI) at baseline compared to nonresponders (p=0.015), and less catastrophizing thoughts (CSQ) (p=0.021). No significant differences were found in any other baseline variables between the groups (Table 1) .
== Table 1 == Change from baseline to after treatment for placebo responders and non-responders
Patients who reported a positive treatment response on PGIC were significantly improved in almost all outcomes measures from before treatment to after treatment, including FM impact (FIQ; p=0.001), average weekly pain intensity (VAS; p=0.001) and pain drawing (p=0.003),
but not for P50 (p=0.865). Conversely, placebo non-responders did not improve in any outcomes; FM impact (p=0.160), average weekly pain intensity (p=0.495), pain drawing (p=0.780) or P50 (p=0.485) ( Table 2 ). This provided validation that the general PGIC categorization of responders and non-responders was consistently reflected in our painspecific outcome measures.
== Table 2 
== Figure 3 ==
Discussion
Here we demonstrate that placebo responses among FM patients in our study were affected by the duration of chronic widespread pain. In line with previous evidence for neural plasticity in 
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reduced pain related activation of rACC 20 and lower functional connectivity between the rACC and other parts of the pain inhibitory network 21 and medial frontal gyrus, which were related to pain intensity, i.e., lower MOR BP were associated with weaker pain related brain activations and higher pain ratings. In our previous study, specifically comparing milnacipran with placebo responders, we found segregated neural mechanisms for the positive response in FM patients 22 . Following treatment, milnacipran responders exhibited significantly increased pain related activation of PCC, associated with reduced pain sensitivity (increased P50) and lower intensities of ongoing pain, whereas placebo responders did not exhibit increased PCC activation, nor, as reported in the present sudy, reduced pain sensitivity. However, both groups had increased pain related activation of the amygdala following treatment. Amygdala has been associated with cannabinoid analgesia mediating the reduction of unpleasantness of ongoing pain, but not reduced pain sensitivity 33 . Thus, our previous fMRI results would indicate that the placebo response associated with clinical improvement in our FM cohort could involve endocannabinoid or possibly dopaminergic mechanisms, both previously implicated in placebo analgesia 11, 24 , rather than endogenous opioids. Hypothetically, these non-opioid mechanisms are less influenced by pain duration and therefore explain the presence of placebo responses also in FM patients with long disease duration.
We did not find any baseline group differences in pain sensitivity (P50) between placebo responders and non-responders, which tallies our previous results
13 significant group differences could be explained by the large inter-individual variability in pressure pain sensitivity, which has been reported also in healthy subjects 29 . Despite the lack of an overall significant increase in P50 within the placebo group, patients with shorter pain duration had larger reductions in pain sensitivity. These results are in accordance with our previous findings that short pain duration was a positive predictor for milnacipran response, associated with significant reductions in pain sensitivity (increased P50) 22 . The present study represents a combination of a traditional drug trial and a mechanistic experimental study, where the benefit of using a highly controlled treatment protocol is combined with the advantage of obtaining quantitative sensory data. Moreover, all patients were washed out of medications, which is not feasible in most experimental studies.
In this study we found that placebo responders had lower ratings of depression at baseline compared to non-responders, and less catastrophizing thoughts (even if depression and catastrophizing had no impact on analyses regarding FM duration). The notion of predicting who will be a placebo responder has intrigued researchers and pharmaceutical companies since the recognition of placebo effects in medicine 40 , yet, there has been no conclusive evidence for a typical placebo responder 26 . In our study, patients with less negative affect at baseline were more likely to be placebo responders, perhaps because they were more likely to form positive expectations about the treatment. Placebo analgesia is closely related to expectations of pain relief and accounts for a large amount of variance in placebo responses 6, 46 . As the contextual factors are likely to vary considerably between trials, and treatment expectations may vary accordingly (i.e. through differences in patient-clinician relationship)
27, 28 , it is unlikely that baseline depression and catastrophizing will always be associated with placebo responses. Yet, if negative affect has a negative influence on the general perception of the credibility of a clinical trial, this may impact placebo outcomes. In contrast to the baseline predictors for placebo responses in FM reported here (depression and catastrophizing), our previous study revealed that predictors of the response to milnacipran (a serotonergic-/noradrenergic drug) was independent of psychological variablesM A N U S C R I P T
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An overall correlation showed that weekly pain levels were less variable over time, leading to more constant pain (in line with previous research suggesting that FM patients are less sensitive to variations in weather with time 13 ). Placebo responders, however, did not display the same transition towards more constant pain levels with longer FM duration. Hence, the overall relationship between less variable pain and FM duration was driven by nonresponders. It is possible that a variable pain profile is favorable for recruiting endogenous pain responses, as pain may still be malleable, in contrast to patients with a less flexible pain modulatory system. It is our hope that future pain studies will include pain variability as a study variable when assessing response to treatment and factors for individualizing treatment.
Future studies and emerging hypotheses
A recent meta-analysis 9 presented a statistical synthesis of 37 FM neuroimaging studies 
Limitations
The present study used a traditional placebo-controlled design, and did not include a natural history control group. This means that the placebo responses could not be controlled for general factors such as spontaneous remission or regression to the mean. Yet, long-term follow up of FM patients indicate small chances of recovery 4, 12 . Another limitation is the small sample. The present study was a secondary analysis of a RCT aimed at comparing pain mechanisms in response to treatment with milnacipran (n=46) and placebo (n=46). Hence the power in the original study was adequate, but in the present subgrouping into placebo responders and non-responders we have poorer power, which restricted the type of analyses we could perform. In a larger study, regression analyses could have provided sophisticated models of the contribution of different factors to placebo responses. In spite of the small sample size, we hope that the present study can be seen as a first indication of a new line of studies that take pain duration into consideration when studying the effects of treatments for chronic pain. 
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